Special Issue "Recent Progress & Critical Challenges in Non-Viral Nucleic Acid Therapy"

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (15 November 2014)

Special Issue Editor

Guest Editor
Dr. Mohamed E.H. ElSayed

Department of Biomedical Engineering & Macromolecular Science and Engineering Program, University of Michigan, 1101 Beal Ave, Lurie Biomedical Engineering Building, Room 2150, Ann Arbor, MI 48109, USA
Website | E-Mail
Interests: targeted therapeutic & diagnostic nano-medicine; cellular & sub-cellular trafficking pathways; drug delivery

Special Issue Information

Dear Colleagues,

Many DNA and RNA sequences have been shown to add, correct, or suppress genes in mammalian cells. These abilities have tremendous potential treating many life-threatening diseases. However, transforming DNA/RNA molecules into safe, stable, and effective therapies with well-defined dosing regimens is still an unaccomplished goal. *Pharmaceuticals* will publish a special issue, entitled "Recent Progress & Critical Challenges in Non-Viral Nucleic Acid Therapy", which aims to provide a comprehensive overview of recent progress in the development of non-viral nucleic acid therapies and the challenges hampering their translation into the clinic. I cordially invite contributions of review articles and original research

papers that discuss any of the following topics:

I)     The development of novel DNA/RNA vectors;

II)    Active and passive targeting strategies of non-viral carriers,

III)  Cell-specific binding, internalization, and sub-cellular trafficking,

IV)   PK/PD considerations for non-viral particles, and

V)     Progress and hurdles in the manufacture of non-viral DNA/RNA therapies.

Dr. Mohamed E.H. ElSayed
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 850 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to Top